Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients

The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction of tyrosine kinase inhibitors (TKI) into clinics, such as midostaurin and gilteritinib. The present work summarizes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Matteo, Perrone, Salvatore, Rossi, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253262/
https://www.ncbi.nlm.nih.gov/pubmed/37297842
http://dx.doi.org/10.3390/jcm12113647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253262/
https://www.ncbi.nlm.nih.gov/pubmed/37297842
http://dx.doi.org/10.3390/jcm12113647

Ejemplares similares